Conference Coverage: ASH 2022 – Focus on Lymphoma

Lymphoma-specific discussions on latest research updates, therapeutic advances, and their application in clinical decision-making.

December 16, 2022


Brad S. Kahl, MD

Washington University School of Medicine, St Louis, MO, USA

Faculty Members

John Allan, MD
Weill Cornell Medicine, New York, NY, USA

Paolo Caimi, MD
Case Comprehensive Cancer Center, Cleveland, OH, USA

Martin Dreyling, MD, PhD
University of Munich Hospital, Großhadern, Germany

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci (UK)
Cancer Research UK Barts Centre, London, UK

Georg Hess, MD
Johannes Gutenberg University, Mainz, Germany

Jasmine Zain, MD
City of Hope, Duarte, CA, USA

Sample Report

Start discovering the insights

View Report


  • Advances in DLBCL/Aggressive B-Cell Lymphoma
  • Advances in Indolent Lymphomas (FL and MZL)
  • Advances in MCL
  • Advances in T-Cell Lymphoma
  • Evolving Use of BTK Inhibitors in CLL
  • Role of Fixed-Duration and MRD-Guided Strategies in CLL

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.